Research Article
Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns
| | Characteristics | Osteosarcoma
() | Soft tissue sarcoma
() |
| | Age, median (range) | 28 (8–62) | 55 (19–76) | | Sex, (%) | | Male | 9 (69) | 12 (39) | | Female | 4 (31) | 19 (61) | | ECOG performance status, (%) | | 0–1 | 10 (77) | 20 (64) | | 2–3 | 3 (23) | 11 (36) | | Primary tumor site, (%) | | Extremities | 12 (92) | 21 (68) | | Trunk | 1 (8) | 10 (32) | | Surgical history, (%) | | Yes | 11 (85) | 25 (81) | | No | 2 (15) | 6 (19) | | Chemotherapy history, (%) | | Yes | 13 (100) | 12 (39) | | No | 0 (0) | 19 (61) | | Radiotherapy history, (%) | | Yes | 0 (0) | 8 (26) | | No | 13 (100) | 23 (74) | | Recurrence, (%) | | Yes | 8 (62) | 21 (68) | | No | 5 (38) | 10 (32) | | Distant metastases, (%) | | Lung only | 8 (62) | 10 (32) | | Other single | 0 (0) | 3 (10) | | Multiple organs | 2 (15) | 2 (6) | | Therapy, (%) | | Anlotinib alone | 7 (54) | 16 (52) | | Anlotinib plus chemotherapy | 6 (46) | 13 (42) | | Anlotinib plus radiotherapy | 0 (0) | 2 (6) | | Treatment lines of anlotinib, (%) | | First line | 2 (15) | 8 (26) | | Second line | 8 (62) | 18 (58) | | Beyond second line | 3 (23) | 5 (16) |
|
|
ECOG: Eastern Cooperative Oncology Group.
|
